IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: In another phase II study,26 the Nordic group randomized 112 chronic phase CML patients with low or intermediate risk who were in complete hematologic remission after therapy with 400mg imatinib to a) continuation with imatinib alone b) receive imatinib plus 50μg pegylated IFNa/week; 34 of the 56 patients in the combination arm discontinued peg-IFNα and the dose of peg-IFN was reduced to 30μg/week.